ArticleBMC oral health2026
Skin levels of advanced glycation end products in correlation with periodontal conditions - a pilot study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough associations between periodontitis and metabolic diseases are established, published data about the correlation of advanced glycation end products (AGEs) and periodontal inflammation are scarce. The aim of the pilot study was to assess the AGE-levels in the skin of patients with gingival (GI: bleeding on probing (BOP) positive, no periodontal pockets), or periodontal inflammation (PE + : BOP-positive with periodontal pockets), or individuals with a history of periodontitis but no signs of current inflammation (PE-: BOP-negative with clinical attachment loss) to evaluate a potential role of AGEs as a biomarker for disease severity and risk of metabolic comorbidities in patients with GI or PE.
methodsAfter an oral examination a total of 168 patients (healthy or with control systemic conditions e.g. diabetes) were classified into a GI (n = 68), PE + (n = 64) and PE- (n = 36) group. AGE levels were measured non-invasively on the skin of the inner forearm using a point-of-care AGE-reader. Cardiovascular (CV) risk was assessed based on numerical AGE read-out in the skin and diabetes risk was determined using the Finnish-Diabetes-Risk-Score (FINDRISC) questionnaire.
resultsSignificantly higher AGE levels were found in PE (2.1(0.6)) versus GI (1.7(0.6) (p < 0.001), whereas no significant association could be identified between the CV risk in PE versus GI (p = 0.196). A subgroup analysis in PE identified a positive association for patients with current gingival inflammation (PE +) and higher CV-risk (p = 0.031). The FINDRISC was higher in PE (10.1(5.1)) compared to GI (6.1(4.9)) (p < 0.001).
conclusionCurrent inflammation in PE is associated with increased CV risk based on AGE levels of the skin. The AGE Reader may serve as a non-invasive screening tool in dental practice to support early CV-risk assessment and interdisciplinary prevention strategies.
trial registrationThe study was retrospectively registered in the DRKS—German Clinical Trials Register ( https://www.drks.de ) with the registration-ID DRKS00031545 (23/03/2023).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.